The Hoosier Cancer Research Network study HCRN GI14-198, a Phase II randomized, double-blind, study of mfolfirinox plus ramucirumab versus mfolfirinox plus placebo in advanced pancreatic cancer patients, was featured as a trials in progress poster during the 2019 Gastrointestinal Cancers Symposium, Jan. 18 in San Francisco, CA. The multi-center study is led by sponsor-investigator Walid Shaib, MD, of the Winship Cancer Institute of Emory University.

Abstract Title:

Phase II randomized, double-blind, study of mfolfirinox plus ramucirumab versus mfolfirinox plus placebo in advanced pancreatic cancer patients. HCRN GI14-198.

Authors:

Walid Labib Shaib, Bert O’Neil, Bassel F. El-Rayes, Steven J. Cohen, Tina Ashley Khair, Erwin L. Robin, Timothy K. Huyck, Rebecca A. Redman, Ashwin Reddy Sama, Mohamad Kassar, Tanios S. Bekaii-Saab; Winship Cancer Institute of Emory University, Atlanta, GA; Indiana University School of Medicine, Indianapolis, IN; Winship Cancer Institute, Emory University, Atlanta, GA; Jefferson Health System/Abington Memorial Hospital, Abington, PA; Gettysburg Cancer Center, Gettysburg, PA; Community Hospital, Munster, IN; Nebraska Cancer Spclsts, Omaha, NE; James Graham Brown Cancer Center, University of Louisville, Louisville, KY; Thomas Jefferson University Hospital, Philadelphia, PA; Northwest Onc PC, Burridge, IL; Mayo Clinic, Phoenix, AZ

See full abstract.

About Hoosier Cancer Research Network:

Hoosier Cancer Research Network (formerly known as Hoosier Oncology Group) conducts innovative cancer research in collaboration with academic and community physicians and scientists across the United States. The organization provides comprehensive clinical trial management and support, from conception through publication. Created in 1984 as a program of the Walther Cancer Institute, Hoosier Cancer Research Network became an independent nonprofit clinical research organization in 2007. Since its founding, Hoosier Cancer Research Network has conducted more than 210 trials in a variety of cancer types and supportive care, resulting in more than 350 publications. More than 8,500 subjects have participated in Hoosier Cancer Research Network clinical trials.